Abstract | OBJECTIVE: To determine whether the coprescribing of two or more antipsychotics, a relatively frequent practice with little data to support its safety and efficacy, is associated with an increased prevalence of metabolic syndrome. METHODS: RESULTS:
Antipsychotic polytherapy was present in 70 patients (19.2%) and was significantly more likely in patients with schizophrenia and those treated with clozapine, quetiapine or ziprasidone (p<0.0001). Compared with antipsychotic monotherapy, polytherapy was associated with elevated rates of metabolic syndrome (50.0% vs. 34.3%, p=0.015) and TG/HDL (50.7% vs. 35.0%, p=0.016). However, in logistic regression analyses, metabolic syndrome was significantly associated with higher body mass index (BMI), older age, a diagnosis of bipolar disorder or schizophrenia, and cotreatment with a first-generation antipsychotic (r(2): 0.25, p<0.0001). The TG/HDL marker of insulin resistance was associated with higher BMI, male sex, Caucasian race and absence of aripiprazole treatment (r(2): 0.14, p<0.0001). Antipsychotic polypharmacy dropped out of both multivariate models. CONCLUSIONS:
|
Authors | Christoph U Correll, Anne M Frederickson, John M Kane, Peter Manu |
Journal | Schizophrenia research
(Schizophr Res)
Vol. 89
Issue 1-3
Pg. 91-100
(Jan 2007)
ISSN: 0920-9964 [Print] Netherlands |
PMID | 17070017
(Publication Type: Journal Article, Research Support, N.I.H., Extramural)
|
Chemical References |
- Antipsychotic Agents
- Cholesterol, HDL
- Dibenzothiazepines
- Piperazines
- Quinolones
- Thiazoles
- Triglycerides
- Quetiapine Fumarate
- ziprasidone
- Aripiprazole
- Clozapine
|
Topics |
- Adult
- Age Factors
- Antipsychotic Agents
(adverse effects, therapeutic use)
- Aripiprazole
- Bipolar Disorder
(blood, drug therapy)
- Body Mass Index
- Cholesterol, HDL
(blood)
- Clozapine
(adverse effects, therapeutic use)
- Cross-Sectional Studies
- Dibenzothiazepines
(adverse effects, therapeutic use)
- Drug Therapy, Combination
- Female
- Humans
- Insulin Resistance
(physiology)
- Male
- Metabolic Syndrome
(blood, chemically induced, diagnosis)
- Middle Aged
- Piperazines
(administration & dosage, adverse effects, therapeutic use)
- Quetiapine Fumarate
- Quinolones
(adverse effects, therapeutic use)
- Risk Factors
- Schizophrenia
(blood, drug therapy)
- Thiazoles
(administration & dosage, therapeutic use)
- Triglycerides
(blood)
|